Last reviewed 2026-05-21 · How we verify

(+/-)-Etozolin (ETOZOLIN)

Phase 2 active Small molecule ✓ Verified May 2026

(+/-)-Etozolin (generic name: ETOZOLIN) is a etozolin drug. It is currently in Phase 2 development.

The mechanism of action of ETOZOLIN is currently unknown.

Etozolin is a small molecule with the synonyms ELKAPIN, ETOZOLIN, ETOZOLINA, and ETOZOLINE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETOZOLIN
Drug class	etozolin
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, we don't know how ETOZOLIN works, but it's a type of small molecule drug that is designed to interact with specific biological targets in the body. This interaction is intended to produce a therapeutic effect, but without more information, it's difficult to say exactly how it works. More research is needed to understand its mechanism of action and how it might be used to treat certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(+/-)-Etozolin CI brief — competitive landscape report
(+/-)-Etozolin updates RSS · CI watch RSS

Frequently asked questions about (+/-)-Etozolin

What is (+/-)-Etozolin?

(+/-)-Etozolin (ETOZOLIN) is a etozolin drug.

How does (+/-)-Etozolin work?

The mechanism of action of ETOZOLIN is currently unknown.

What is the generic name of (+/-)-Etozolin?

ETOZOLIN is the generic (nonproprietary) name of (+/-)-Etozolin.

What drug class is (+/-)-Etozolin in?

(+/-)-Etozolin belongs to the etozolin class. See all etozolin drugs at /class/etozolin.

What development phase is (+/-)-Etozolin in?

(+/-)-Etozolin is in Phase 2.

Drug class: All etozolin drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing